Prothena Corp. (PRTA) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
February 12, 2020 4:06 PM ESTNet cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash position of $378.4 million provides funding to advance a broad pipeline
Reported interim data from Phase 1 study of PRX004 in patients with hereditary ATTR amyloidosis
DUBLIN, Ireland, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financial results for the fourth quarter and full year... More
